Virax Biolabs increased the maximum aggregate amount of ordinary shares it may sell through H.C. Wainwright to $2,070,060.20, excluding $3,658,152 previously sold under the agreement. The change gives investors a larger stated share-sale capacity under the existing arrangement, subject to applicable securities-law registration or qualification requirements.
Key Highlights
- Virax Biolabs entered its At The Market Offering Agreement with H.C. Wainwright on January 22, 2024.
- The ordinary shares carry a Par Value of $0.025 per share.
- The prospectus supplement amending the offering was dated September 4, 2026.
Virax Biolabs Group Ltd (NASDAQ: VRAX) increased the maximum aggregate value of ordinary shares available for sale under its At The Market Offering Agreement to $2,070,060.20.
Prospectus Sets Offering Terms
H.C. Wainwright & Co. LLC serves as Virax Biolabs’ sales agent under the agreement, which permits the company to offer ordinary shares from time to time. The securities have a par value of $0.025 per share. The arrangement was established on January 22, 2024. The updated prospectus supplement amends materials dated January 22, 2024, September 30, 2024, and December 15, 2023. Those documents form part of Virax Biolabs’ effective registration statement, identified by File No. 333-275893.
Expanded Capacity Governs Future Sales
The revised ceiling gives Virax Biolabs the stated ability to conduct additional ordinary-share sales through H.C. Wainwright under the existing Sales Agreement. The $2,070,060.Any offer, solicitation or sale remains subject to registration or qualification requirements under applicable securities laws.
FAQs
Q: What is Virax Biolabs’ new ATM offering amount?
A: Virax Biolabs may offer and sell up to $2,070,060.20 of ordinary shares through H.C. Wainwright under its At The Market Offering Agreement.
Q: How much stock did Virax Biolabs previously sell under the agreement?
A: Virax Biolabs previously sold $3,658,152 of ordinary shares under the Sales Agreement. That amount is excluded from the revised $2,070,060.20 maximum.
Q: Who is Virax Biolabs’ sales agent?
A: H.C. Wainwright & Co. LLC is the sales agent for Virax Biolabs’ ordinary-share offering. The agreement allows sales to occur from time to time.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.